(UroToday.com) Advanced urothelial carcinoma carries among the worst prognoses for tumors treated by genitourinary oncologists. Standard of care dictates that patients receive platinum-based induction chemotherapy. However, even with this treatment, rates of recurrence and disease progression are high and overall survival is quite short due to the development of chemotherapy resistance. In the JAVELIN Bladder 100 study which was reported at ASCO 2020 Virtual Annual Meeting and subsequently published in the New England Journal of Medicine, the addition of avelumab, a PD-L1 directed therapy, maintenance to best supportive care following induction chemotherapy demonstrated improvements in overall survival for patients who did no have disease progression during their initial cytotoxic chemotherapy induction.